Although the Von Hippel-Lindau (VHL) tumor suppressor is the most frequently detected mutation in ccRCC associated with the development and progression of RCC, little is known about genomic alterations and their impact on the therapeutic response of different treatment agents [10]. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.